Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)-Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)-Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women.
Συγγραφείς:	Perciani CT; Department of Immunology, University of Toronto, Ontario, Canada., Sekhon M; Department of Immunology, University of Toronto, Ontario, Canada., Hundal S; Department of Immunology, University of Toronto, Ontario, Canada., Farah B; Kenyan AIDS Vaccine Initiative-Institute of Clinical Research, Nairobi, Kenya., Ostrowski MA; Department of Immunology, University of Toronto, Ontario, Canada.; Keenan Research Centre for Biomedical Science of St Michael's Hospital, Toronto, Ontario, Canada., Anzala AO; Kenyan AIDS Vaccine Initiative-Institute of Clinical Research, Nairobi, Kenya.; Department of Medical Microbiology, University of Nairobi, Kenya., McKinnon LR; Department of Medical Microbiology, University of Nairobi, Kenya.; Department of Medical Microbiology and Infectious Diseases, Rady College of Medicine, University of Manitoba, Winnipeg, Canada.; Centre for the AIDS Programme of Research in South Africa, Durban., Jaoko W; Kenyan AIDS Vaccine Initiative-Institute of Clinical Research, Nairobi, Kenya.; Department of Medical Microbiology, University of Nairobi, Kenya., MacDonald KS; Department of Immunology, University of Toronto, Ontario, Canada.; Section of Infectious Diseases, Department of Internal Medicine, Rady College of Medicine, University of Manitoba, Winnipeg, Canada.
Συλλογικό Έργο:	Institute of Tropical and Infectious Diseases (UNITID) Group and the Kenyan AIDS Vaccine Initiative–Institute of Clinical Research (KAVI-ICR) Team
Πηγή:	The Journal of infectious diseases [J Infect Dis] 2018 Sep 08; Vol. 218 (8), pp. 1210-1218.
Τύπος έκδοσης:	Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE
Imprint Name(s):	Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press
Ιατρικοί όροι (MeSH):	Immunity, Humoral, Antibodies, Viral/metabolism , Herpesvirus 3, Human/isolation & purification , Mucous Membrane/immunology , Vagina/immunology , Varicella Zoster Virus Infection/prevention & control, Antibodies, Viral/blood ; Herpes Zoster Vaccine/immunology ; Kenya/epidemiology ; Varicella Zoster Virus Infection/epidemiology ; Varicella Zoster Virus Infection/immunology ; Female ; Humans ; Vaccines, Attenuated
Περίληψη:	Background: Attenuated varicella zoster virus (VZV) is a promising vector for recombinant vaccines. Because human immunodeficiencyvirus (HIV) vaccines are believed to require mucosal immunogenicity, we characterized mucosal VZV-specific humoral immunity following VZVOka vaccination. Methods: Adult Kenyan VZV-seropositive women (n = 44) received a single dose of the live zoster VZVOka vaccine. The anamnestic responses to the virus were followed longitudinally in both plasma and mucosal secretions using an in-house glycoprotein enzyme-linked immunosorbent assay and safety and reactogenicity monitored. VZV seroprevalence and baseline responses to the virus were also characterized in our cohorts (n = 288). Results: Besides boosting anti-VZV antibody responses systemically, vaccination also boosted anti-VZV immunity in the cervicovaginal mucosa with a 2.9-fold rise in immunoglobulin G (P < .0001) and 1.6-fold rise in immunoglobulin A (IgA) (P = .004) from the time before immunization and 4 weeks postvaccination. Baseline analysis demonstrated high avidity antibodies at the gastrointestinal and genital mucosa of VZV-seropositive women. Measurement of VZV-specific IgA in saliva is a sensitive tool for detecting prior VZV infection. Conclusions: VZVOka vaccine was safe and immunogenic in VZV-seropositive adult Kenyan women. We provided compelling evidence of VZV ability to induce genital mucosa immunity. Clinical Trials Registration: NCT02514018.
References:	J Infect Dis. 2008 Mar 1;197 Suppl 2:S61-5. (PMID: 18419411) Vaccine. 2006 Nov 17;24(47-48):6875-85. (PMID: 17050042) BMJ Open. 2016 Apr 20;6(4):e010213. (PMID: 27098823) Pediatr Infect Dis J. 2002 Apr;21(4):337-42. (PMID: 12075766) J Infect Dis. 1998 Nov;178 Suppl 1:S52-4. (PMID: 9852974) Mucosal Immunol. 2018 Mar;11(2):512-522. (PMID: 28792003) J Clin Virol. 2009 Jan;44(1):9-14. (PMID: 18823815) Clin Diagn Lab Immunol. 1996 May;3(3):365-7. (PMID: 8705687) Curr Top Microbiol Immunol. 2010;342:189-209. (PMID: 20397071) J Infect Dis. 2011 Oct 1;204(7):1075-85. (PMID: 21881123) BMJ Open. 2017 Sep 21;7(9):e017391. (PMID: 28939581) J Infect Dis. 2008 Mar 15;197(6):825-35. (PMID: 18419349) N Engl J Med. 2005 Jun 2;352(22):2271-84. (PMID: 15930418) J Infect Dis. 2014 Nov 15;210(10):1573-81. (PMID: 24823623) J Clin Invest. 2014 Jul;124(7):3147-58. (PMID: 24911151) Adv Virol. 2013;2013:219439. (PMID: 23843791) J Immunol. 2014 Sep 15;193(6):3126-33. (PMID: 25143442) Lancet. 1974 Nov 30;2(7892):1288-90. (PMID: 4139526) J Infect Dis. 1996 Nov;174 Suppl 3:S314-9. (PMID: 8896538) PLoS Pathog. 2016 Dec 13;12(12):e1006104. (PMID: 27959961) Trends Immunol. 2014 Nov;35(11):526-37. (PMID: 25113637) J Med Virol. 2012 Dec;84(12):2018-25. (PMID: 23080511) JAMA. 2005 Aug 17;294(7):797-802. (PMID: 16106004) N Engl J Med. 2015 May 28;372(22):2087-96. (PMID: 25916341) J Clin Lab Anal. 2007;21(3):201-6. (PMID: 17506479) J Am Osteopath Assoc. 2009 Jun;109(6 Suppl 2):S13-7. (PMID: 19553630) J Infect Dis. 2011 Feb 1;203(3):312-5. (PMID: 21208922) J Immunol. 2014 Sep 15;193(6):3113-25. (PMID: 25135832) N Engl J Med. 2005 Feb 3;352(5):450-8. (PMID: 15689583)
Grant Information:	THA-11960 Canada CIHR
Contributed Indexing:	Investigator: J Kimano; J Oyugi; E Irungu; J Nyakio; R Malogo; R Mahira; G Mutua; L Atambo; B Nyaoke; J Nyange; J Omungo; T Kotikot; MW Gichuho; H Ogutu; R Ndambuki; E Museve; HN Gakure; D Essendi; E Mutiska; B Onsembe; M Akiso; S Ogola; N Wanjiku; R Langat; J Indangasi; N Mwakisha; I Mwangi; M Agwaya; R Chirchir; R Alila; L Said; J Wakonyo; M Musanga; C Kamau; M Muriuki; J Ndalamia; C Ngeli; L Lusik
Molecular Sequence:	ClinicalTrials.gov NCT02514018
Substance Nomenclature:	0 (Antibodies, Viral) 0 (Herpes Zoster Vaccine) 0 (Vaccines, Attenuated)
Entry Date(s):	Date Created: 20180526 Date Completed: 20190916 Latest Revision: 20190916
Update Code:	20260130
PubMed Central ID:	PMC6129112
DOI:	10.1093/infdis/jiy320
PMID:	29800309
Βάση Δεδομένων:	MEDLINE

Full Text Finder

Περιγραφή
ISSN:	1537-6613
DOI:	10.1093/infdis/jiy320